• Gyre Therapeutics completed acquisition of privately held Cullgen in an all-stock transaction valued at about USD 300 million, creating a U.S.- and China-based biopharmaceutical company.
• Cullgen became a wholly owned subsidiary; former Cullgen CEO Ying Luo was appointed Gyre president and CEO, joining board, while Ping Zhang remains chairman.
• Combined group retains Nasdaq listing under ticker GYRE, adding Cullgen targeted protein degrader and degrader-antibody conjugate platform to Gyre fibrosis and inflammatory disease portfolio.
• Portfolio includes China-marketed lung fibrosis drug ETUARY, lead liver fibrosis candidate F351 (hydronidone) with an NDA under priority review in China, ETUARY Phase 3 trial enrollment completed in pneumoconiosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040847PRIMZONEFULLFEED9712293) on May 04, 2026, and is solely responsible for the information contained therein.